Biogen Idec (BIIB) Says CONFIRM Phase 3 for BG-12 Met Endpoints in Second Trial
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen Idec (Nasdaq: BIIB) announced that detailed positive data from CONFIRM, the second Phase 3 clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS), will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans.
In CONFIRM, BG-12 demonstrated efficacy across a variety of clinical and radiological outcome measures, as well as favorable safety and tolerability profiles. These data, along with results from BG-12’s first Phase 3 study, DEFINE, were included in regulatory applications that were submitted to U.S. and EU regulatory agencies early this year.
CONFIRM was a global, placebo-controlled clinical trial to determine the efficacy and safety of 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), in people with RRMS. The study included glatiramer acetate (GA; 20 mg subcutaneous daily injection) as a reference comparator. Both active treatments were compared to placebo.
BG-12 met the CONFIRM study’s primary endpoint by significantly reducing annualized relapse rate (ARR) by 44 percent for BID and by 51 percent for TID (p<0.0001 for both) compared to placebo over two years. GA reduced ARR by 29 percent (p=0.0128) compared to placebo over two years.
BG-12 met the study’s secondary relapse endpoint by significantly reducing the proportion of patients who relapsed at two years by 34 percent for BID (p=0.0020) and by 45 percent for TID (p<0.0001) compared to placebo. GA provided a 29 percent reduction (p=0.0097) in the proportion of relapsing patients compared to placebo over the same time period.
BG-12 also met magnetic resonance imaging (MRI) endpoints in a cohort of patients, demonstrating a significant effect on MS brain lesions. Reductions in new brain lesion counts were evident within the first year of treatment and were sustained throughout the study. At two years compared to placebo:
In CONFIRM, BG-12 demonstrated efficacy across a variety of clinical and radiological outcome measures, as well as favorable safety and tolerability profiles. These data, along with results from BG-12’s first Phase 3 study, DEFINE, were included in regulatory applications that were submitted to U.S. and EU regulatory agencies early this year.
CONFIRM was a global, placebo-controlled clinical trial to determine the efficacy and safety of 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), in people with RRMS. The study included glatiramer acetate (GA; 20 mg subcutaneous daily injection) as a reference comparator. Both active treatments were compared to placebo.
BG-12 met the CONFIRM study’s primary endpoint by significantly reducing annualized relapse rate (ARR) by 44 percent for BID and by 51 percent for TID (p<0.0001 for both) compared to placebo over two years. GA reduced ARR by 29 percent (p=0.0128) compared to placebo over two years.
BG-12 met the study’s secondary relapse endpoint by significantly reducing the proportion of patients who relapsed at two years by 34 percent for BID (p=0.0020) and by 45 percent for TID (p<0.0001) compared to placebo. GA provided a 29 percent reduction (p=0.0097) in the proportion of relapsing patients compared to placebo over the same time period.
BG-12 also met magnetic resonance imaging (MRI) endpoints in a cohort of patients, demonstrating a significant effect on MS brain lesions. Reductions in new brain lesion counts were evident within the first year of treatment and were sustained throughout the study. At two years compared to placebo:
- BG-12 reduced the number of new or newly enlarging T2-hyperintense lesions (secondary endpoint) by 71 percent for BID (p<0.0001) and by 73 percent for TID (p<0.0001), while GA provided a 54 percent reduction (p<0.0001).
- BG-12 reduced the number of new non-enhancing T1-hypointense lesions (secondary endpoint) by 57 percent for BID (p<0.0001) and by 65 percent for TID (p<0.0001), while GA provided a 41 percent reduction (p=0.0021).
- BG-12 reduced the odds of having more gadolinium-enhancing (Gd+) lesions (tertiary endpoint) by 74 percent for BID (p<0.0001) and by 65 percent for TID (p=0.0001), while GA provided a 61 percent reduction (p=0.0003).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- PPG names three segment leaders effective September 2026
- Bitdeer AI signs $400M deal, targets 350MW data center capacity
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
